[
    {
        "molecule_name": "anti-RAGE antibodies",
        "protein_target_name": "RAGE",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "1×10−7",
        "unit": "M",
        "raw_mentions": "The invention includes anti-RAGE antibodies that bind specifically to RAGE-expressing cells in vitro and in vivo, and antibodies that bind to human RAGE with a dissociation constant (Kd) in the range of from at least about 1×10<sup>−7 </sup>M to about 1×10<sup>−10 </sup>M."
    },
    {
        "molecule_name": "anti-RAGE antibodies",
        "protein_target_name": "RAGE",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Kd",
        "value": "1×10−10",
        "unit": "M",
        "raw_mentions": "The invention includes anti-RAGE antibodies that bind specifically to RAGE-expressing cells in vitro and in vivo, and antibodies that bind to human RAGE with a dissociation constant (Kd) in the range of from at least about 1×10<sup>−7 </sup>M to about 1×10<sup>−10 </sup>M."
    }
]